Geron Corp (NASDAQ:GERN)

CAPS Rating: 2 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar TruffelPig (< 20) Submitted: 10/5/2012 8:08:20 PM : Underperform Start Price: $1.41 GERN Score: +2.02

Going, going, going.....gone?

Featured Broker Partners


Advertisement